[go: up one dir, main page]

TR200003635T2 - Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması. - Google Patents

Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.

Info

Publication number
TR200003635T2
TR200003635T2 TR2000/03635T TR200003635T TR200003635T2 TR 200003635 T2 TR200003635 T2 TR 200003635T2 TR 2000/03635 T TR2000/03635 T TR 2000/03635T TR 200003635 T TR200003635 T TR 200003635T TR 200003635 T2 TR200003635 T2 TR 200003635T2
Authority
TR
Turkey
Prior art keywords
treatment
ribavirin
ifn
peg
chronic hepatitis
Prior art date
Application number
TR2000/03635T
Other languages
English (en)
Inventor
Zahm Friederike
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200003635(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR200003635T2 publication Critical patent/TR200003635T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut bulus,kronik hepatit C enfeksiyonlarinin tedavisi için olan ilaçlarin yapimi için PEG-IFN-a konjugatlarin Ribavirin ile birlikte kullanilmasini sunar. Mevcut bulus ayrica, kronik hepatit C tedavisine gereksinim duyan hastalarda kronik hepatit C'nin tedavi edilmesi için PEG-IFN-a konjugatlarin bir miktarinin hepatit C'nin tedavi edilmesinde etkili olan bir miktarinin Ribavirin'in bir miktarinin uygulanmasini içerir.
TR2000/03635T 1998-06-08 1999-05-29 Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması. TR200003635T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98110433 1998-06-08

Publications (1)

Publication Number Publication Date
TR200003635T2 true TR200003635T2 (tr) 2001-04-20

Family

ID=8232086

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03635T TR200003635T2 (tr) 1998-06-08 1999-05-29 Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.

Country Status (34)

Country Link
US (3) US20030053986A1 (tr)
EP (1) EP1087778B1 (tr)
JP (2) JP3839667B2 (tr)
KR (2) KR20050055053A (tr)
CN (1) CN1170543C (tr)
AR (1) AR019855A1 (tr)
AT (1) ATE307597T1 (tr)
AU (1) AU767131B2 (tr)
BR (1) BR9911076A (tr)
CA (1) CA2334267C (tr)
CL (1) CL2010000828A1 (tr)
CO (1) CO5050297A1 (tr)
CZ (1) CZ298681B6 (tr)
DE (1) DE69927971T2 (tr)
DK (1) DK1087778T3 (tr)
ES (1) ES2251196T3 (tr)
HR (1) HRP20000808A2 (tr)
HU (1) HU228218B1 (tr)
ID (1) ID29285A (tr)
IL (2) IL139786A0 (tr)
MA (1) MA26641A1 (tr)
MY (1) MY124091A (tr)
NO (1) NO325598B1 (tr)
NZ (1) NZ508249A (tr)
PE (1) PE20000560A1 (tr)
PL (1) PL192364B1 (tr)
RS (1) RS50144B (tr)
RU (1) RU2271217C2 (tr)
SA (1) SA99200208B1 (tr)
SI (1) SI1087778T1 (tr)
TR (1) TR200003635T2 (tr)
TW (1) TWI241913B (tr)
WO (1) WO1999064016A1 (tr)
ZA (1) ZA200006814B (tr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508249A (en) * 1998-06-08 2003-02-28 F Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CA2410579C (en) 2000-05-26 2010-04-20 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses
ATE348628T1 (de) * 2000-08-07 2007-01-15 Sciclone Pharmaceuticals Inc Behandlung von hepatitis c mit thymosin, interferon und ribavirin
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
KR100480429B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
RS114004A (sr) 2002-06-28 2007-02-05 Idenix (Cayman) Limited, Modifikovani 2'i 3'-nukleozid prolekovi za lečenje flaviridae infekcija
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
JP2006514038A (ja) * 2002-12-23 2006-04-27 イデニクス（ケイマン）リミテツド ３’−ヌクレオシドプロドラッグの生産方法
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
JP2008503562A (ja) * 2004-06-23 2008-02-07 イデニクス（ケイマン）リミテツド フラビウイルス科による感染症を治療するための５−アザ−７−デアザプリン誘導体
US7640048B2 (en) 2004-07-13 2009-12-29 Dexcom, Inc. Analyte sensor
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
JP5001842B2 (ja) 2004-09-14 2012-08-15 ギリアド ファーマセット エルエルシー ２’−フルオロ−２’−アルキル−置換又は他の置換されていてもよいリボフラノシルピリミジン類及びプリン類並びにそれらの誘導体の製造
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007020195A2 (en) * 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Peg-ifn alpha and ribavirin for hbv treatment
US9201979B2 (en) * 2005-09-14 2015-12-01 Millennial Media, Inc. Syndication of a behavioral profile associated with an availability condition using a monetization platform
EP1976382B1 (en) * 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
JP5711118B2 (ja) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
JP5539363B2 (ja) * 2008-09-17 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ
CL2009002208A1 (es) 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
KR20110104074A (ko) 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
JP2013501033A (ja) 2009-08-05 2013-01-10 ピエリス アーゲー リポカリン突然変異タンパク質の制御放出製剤
JP2013508425A (ja) 2009-10-30 2013-03-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｉ２０１３３５、インターフェロンアルファおよびリバビリンを含むｈｃｖの併用療法のための投薬処置計画
RU2564125C2 (ru) 2009-12-07 2015-09-27 Пирис Аг Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
HUE043835T2 (hu) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh IL-4 receptor-alfát kötõ könny-lipokalin muteinek
DK2606061T3 (da) 2010-08-16 2017-11-06 Pieris Pharmaceuticals Gmbh Bindingsproteiner til hepcidin
AU2011331232B2 (en) 2010-11-15 2015-05-07 Pieris Ag Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
DK2646552T3 (en) 2010-12-02 2017-10-23 Pieris Pharmaceuticals Gmbh MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4
AP2014007575A0 (en) 2011-09-16 2012-04-30 Gilead Pharmasset Llc Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN109432402B (zh) 2011-12-13 2022-04-29 皮里斯制药有限公司 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
US20140039923A1 (en) * 2012-08-03 2014-02-06 AxelaCare Health Solutions, Inc. Computer program, method, and system for receiving and managing patient data gathered during patient treatments
EP3441400B1 (en) 2012-11-19 2022-07-20 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014140210A1 (en) 2013-03-14 2014-09-18 Pieris Ag Novel binding proteins for pcsk9
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
EP3094650A2 (en) 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
RU2723034C2 (ru) 2014-05-22 2020-06-08 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новые полипептиды со специфическим связыванием и пути их применения
WO2016120307A1 (en) 2015-01-28 2016-08-04 Pieris Ag Novel proteins specific for angiogenesis
WO2016131804A1 (en) 2015-02-18 2016-08-25 Sanofi Novel proteins specific for pyoverdine and pyochelin
DK3292137T3 (da) 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh Proteiner specifikke for cd137
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
BR112017020961A2 (pt) 2015-05-18 2018-07-10 Pieris Pharmaceuticals Gmbh muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação
CA2980838A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
AU2016293101B2 (en) 2015-07-15 2022-06-16 Pieris Pharmaceuticals Gmbh Novel proteins specific for LAG-3
SG11201803732PA (en) 2015-11-30 2018-06-28 Pieris Australia Pty Ltd Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
JP7225116B2 (ja) 2017-01-18 2023-02-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン
PL3830120T3 (pl) 2018-07-31 2023-10-09 Pieris Pharmaceuticals Gmbh NOWE BIAŁKO FUZYJNE SWOISTE WOBEC CD137 i PD-L1
EP3931209A1 (en) 2019-02-26 2022-01-05 Pieris Pharmaceuticals GmbH Novel fusion proteins specific for cd137 and gpc3
WO2021245240A1 (en) 2020-06-05 2021-12-09 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb
JP2024515564A (ja) 2021-04-08 2024-04-10 ピエリス ファーマシューティカルズ ゲーエムベーハー 結合組織増殖因子（ｃｔｇｆ）に特異的な新規リポカリンムテイン
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
IL319272A (en) 2022-09-21 2025-04-01 Seagen Inc ROVEL FUSION protein specific for CD137 and CD228
WO2025175123A1 (en) 2024-02-16 2025-08-21 Seagen Inc. Methods of treating cancer using fusion proteins specific for cd137 and cd228

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (de) * 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5238915A (en) * 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
KR960705579A (ko) * 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
JP2000507917A (ja) * 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
NZ508249A (en) * 1998-06-08 2003-02-28 F Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C

Also Published As

Publication number Publication date
US20070196385A1 (en) 2007-08-23
ATE307597T1 (de) 2005-11-15
BR9911076A (pt) 2001-02-20
YU77000A (sh) 2003-08-29
IL139786A0 (en) 2002-02-10
HU228218B1 (en) 2013-02-28
CN1305382A (zh) 2001-07-25
CZ20004487A3 (en) 2001-06-13
US20050031589A1 (en) 2005-02-10
SA99200208B1 (ar) 2006-08-15
PE20000560A1 (es) 2000-07-05
JP3839667B2 (ja) 2006-11-01
CL2010000828A1 (es) 2011-02-11
KR20050055053A (ko) 2005-06-10
CN1170543C (zh) 2004-10-13
JP2002517451A (ja) 2002-06-18
NO20006178L (no) 2000-12-05
HUP0102033A2 (hu) 2001-10-28
KR20010052622A (ko) 2001-06-25
ID29285A (id) 2001-08-16
IL139786A (en) 2007-10-31
NO325598B1 (no) 2008-06-23
NO20006178D0 (no) 2000-12-05
AR019855A1 (es) 2002-03-20
HRP20000808A2 (en) 2001-10-31
CO5050297A1 (es) 2001-06-27
HUP0102033A3 (en) 2010-01-28
EP1087778A1 (en) 2001-04-04
AU4503399A (en) 1999-12-30
RU2271217C2 (ru) 2006-03-10
CZ298681B6 (cs) 2007-12-19
MA26641A1 (fr) 2004-12-20
MY124091A (en) 2006-06-30
CA2334267C (en) 2009-02-17
RS50144B (sr) 2009-03-25
US20030053986A1 (en) 2003-03-20
CA2334267A1 (en) 1999-12-16
TWI241913B (en) 2005-10-21
DE69927971D1 (de) 2005-12-01
EP1087778B1 (en) 2005-10-26
SI1087778T1 (sl) 2006-02-28
ZA200006814B (en) 2002-05-03
NZ508249A (en) 2003-02-28
WO1999064016A1 (en) 1999-12-16
HK1037981A1 (en) 2002-03-01
ES2251196T3 (es) 2006-04-16
DE69927971T2 (de) 2006-07-27
DK1087778T3 (da) 2005-12-19
PL344794A1 (en) 2001-11-19
PL192364B1 (pl) 2006-10-31
AU767131B2 (en) 2003-10-30
JP2006160759A (ja) 2006-06-22

Similar Documents

Publication Publication Date Title
TR200003635T2 (tr) Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
MY141594A (en) 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
PT956861E (pt) Terapia combinada compreendendo ribavirina e interferao alfa em doentes sem tratamento antiviral anterior tendo infeccao cronica pelo virus da hepatite c
DK0880350T3 (da) Behandling af dissemineret sklerose
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
BG106057A (en) Method of enhancing the efficacy of anti-tumour agents
TR200101085T2 (tr) Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
DE69835824D1 (de) Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
DE69821498D1 (de) Verwendung von amifostin
MD990258A (en) Method of treatment of the acute viral hepatitis B
ATE199641T1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
BR9913951A (pt) Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir
MY124071A (en) Treatment of viral disease in swine
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
PE20010026A1 (es) Composicion que comprende interferon alfa pegilado
TR199801798T2 (tr) Otizm tedavisi.
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
CY1106388T1 (el) Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη
MD980129A (en) Antiherpetic remedy
TW200740455A (en) PEG-IFN alpha and ribavirin for HBV treatment
MA23429A1 (fr) Novelle forme galenique de derives de 5-nitro imidazole efficace pour le traitement des parasitoses et des infections de l'ensemble du tractus-gastro-intestinal.
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
PT1150981E (pt) Composto nucleosidico terapeutico